The short version of receptor targets fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
== Reactions and uses == Vinyl sulfones are dienophiles. Subsequent to the cycloaddition to a vinyl sulfone, the phenylsulfonyl group can be removed by reduction with zinc. Vinyl sulfones are Michael acceptors. Vinyl sulfones add thiols, such as cysteine residues. This same reactive nature is responsible for their major industrial use in vinyl sulfone dyes. Phenyl vinyl sulfone has been applied to ruthenium chemistry as part of olefin metathesis reactions. Vinyl sulfone has applications to protein purification, especially when linked with mercaptoethanol.
According to this equation, maximum resolution is reached when the electrophoretic and electroosmotic mobilities are similar in magnitude and opposite in sign. In addition, it can be seen that high resolution requires lower velocity and, correspondingly, increased analysis time. Besides diffusion and Joule heating (discussed above), factors that may decrease the resolution in capillary electrophoresis from the theoretical limits in the above equation include, but are not limited to, the finite widths of the injection plug and detection window; interactions between the analyte and the capillary wall; instrumental non-idealities such as a slight difference in height of the fluid reservoirs leading to siphoning; irregularities in the electric field due to, e.g., imperfectly cut capillary ends; depletion of buffering capacity in the reservoirs; and electrodispersion (when an analyte has higher conductivity than the background electrolyte). Identifying and minimizing the numerous sources of band broadening is key to successful method development in capillary electrophoresis, with the objective of approaching as close as possible to the ideal of diffusion-limited resolution.
==== Innate immune system ==== There are many regulators which affect immune system and help to keep it balanced. If the immune system is too active there is a danger of developing an autoimmune disease, while passive immune system will lead to infections or cancer. Antigen presenting is a key role in activation of immune system. It has been discovered that AEP plays role in this critical moment. AEP is involved in presenting of foreign and self proteins using MHCII protein complex. The role of AEP in immunity is not clear, but it seems that it is connected with checkpoint inhibitors such as PD-1, which downregulates AEP which is key to shifting the balance between cancer fighting cells and regulatory T cells. In the absence of AEP, inhibitory checkpoints may not have a beneficial response. Measuring of this enzyme in patients could predict which one of them may provide better response to treatment.
== Flow velocity == The solution of the equations is a flow velocity. It is a vector field—to every point in a fluid, at any moment in a time interval, it gives a vector whose direction and magnitude are those of the velocity of the fluid at that point in space and at that moment in time. It is studied in three spatial dimensions and one time dimension, and higher-dimensional analogues are studied in both pure and applied mathematics. Once the velocity field is calculated, other quantities of interest, such as pressure or temperature, may be found using dynamical equations and relations. This is different from what one normally sees in classical mechanics, where solutions are typically trajectories of the position of a particle or deflection of a continuum. Studying velocity instead of position makes more sense for a fluid, although for visualization purposes, one can compute various trajectories. In particular, the streamlines of a vector field, interpreted as flow velocity, are the paths along which a massless fluid particle would travel. These paths are the integral curves whose derivative at each point is equal to the vector field, and they can represent visually the behavior of the vector field at a point in time.
=== Everton bid === In September 2023, 777 Partners agreed to buy Farhad Moshiri's 94.1% shareholding in English Premier League team Everton F.C. In April 2024, with the deal not complete and after the 777-owned Australian airline Bonza entered voluntary administration, Everton called upon the services of insolvency advisers Teneo. Amid lawsuits against 777 Partners in other countries, the Everton Shareholders' Association wrote to Moshiri requesting that he terminate the deal. 777 enlisted B. Riley Financial for advice to complete the deal. According to 777's own lawyers, Wander and Pasko resigned as managers of the company on May 6, 2024, but remained as its 100% owners. On June 1, 2024, the deadline for the deal to be completed expired.
Sources: en.wikipedia.org
Hereditary fibrinogen Aα-Chain amyloidosis is an autosomal dominant extremely rare inherited disorder caused by a mutation in one of the two copies of the FGA gene. It is a form of congenital dysfibrinogenemia in which certain mutations lead to the production of an abnormal fibrinogen that circulates in the blood while gradually accumulating in the kidney. This accumulation leads over time to one form of familial renal amyloidosis. Plasma fibrinogen levels are similar to that seen in other forms of congenital dysfibrinogenemia. Fibrinogen Aα-Chain amyloidosis has not associated with abnormal bleeding or thrombosis.
The Air Force School is a co-educational public school. The school is affiliated to the Central Board of Secondary Education and students are prepared for the All India Secondary School Examination (Class X) and the All India Senior School Certificate Examination (Class XII). The School is a member of the Indian Public Schools' Conference (IPSC) and also of National Progressive Schools' Conference (NPSC).
Earth lodge – A semi-subterranean dwelling with a heavy timber frame covered by layers of willow, grass, and earth, developed by Indigenous peoples of the Great Plains. The earliest true earth lodges were built in the early 1500s along the Missouri River by ancestors of the Mandan and Arikara, as a response to the cooling temperatures of the Little Ice Age. With diameters of up to 60 feet (18 m), they were the largest and most complex structures built on the Plains until the 20th century. In Pawnee culture, earth lodges served as astronomical observatories and were symbolically designed to represent the cosmos. Electroless plating – The Moche independently developed an advanced chemical gilding technique around 100-500 CE that produced results resembling modern electroplating, though it used no battery or external electrical current. The process involved dissolving gold into a chemical solution using naturally occurring minerals such as ferric sulfate and alum. Electroless plating predated electroplating (which requires an external power source) by approximately 1,700 years. True electroplating was not developed until around 1800 CE following Alessandro Volta's invention of the battery. Embalming – Egyptians are known for mummification, which began around 6000 BCE to 600 CE. In what is now Chile, however, the Chinchorro peoples are known to have been embalming and mummifying their dead since around 5000 BCE. Embalming is using preservatives to prevent decay of the body.
=== EC 2.6.1: Transaminases === EC 2.6.1.1: aspartate transaminase EC 2.6.1.2: alanine transaminase EC 2.6.1.3: cysteine transaminase EC 2.6.1.4: glycine transaminase EC 2.6.1.5: tyrosine transaminase EC 2.6.1.6: leucine transaminase EC 2.6.1.7: kynurenine—oxoglutarate transaminase EC 2.6.1.8: deleted EC 2.6.1.9: histidinol-phosphate transaminase EC 2.6.1.10: deleted, included with EC 2.6.1.21, D-amino-acid transaminase EC 2.6.1.11: acetylornithine transaminase EC 2.6.1.12: alanine—oxo-acid transaminase EC 2.6.1.13: ornithine aminotransferase EC 2.6.1.14: asparagine—oxo-acid transaminase EC 2.6.1.15: glutamine—pyruvate transaminase EC 2.6.1.16: glutamine—fructose-6-phosphate transaminase (isomerizing) EC 2.6.1.17: succinyldiaminopimelate transaminase EC 2.6.1.18: β-alanine—pyruvate transaminase EC 2.6.1.19: 4-aminobutyrate transaminase EC 2.6.1.20: deleted EC 2.6.1.21: D-amino-acid transaminase EC 2.6.1.22: (S)-3-amino-2-methylpropionate transaminase EC 2.6.1.23: 4-hydroxyglutamate transaminase EC 2.6.1.24: diiodotyrosine transaminase EC 2.6.1.25: deleted, Now included with EC 2.6.1.24 diiodotyrosine transaminase EC 2.6.1.26: thyroid-hormone transaminase EC 2.6.1.27: tryptophan transaminase EC 2.6.1.28: tryptophan—phenylpyruvate transaminase EC 2.6.1.29: diamine transaminase EC 2.6.1.30: pyridoxamine—pyruvate transaminase EC 2.6.1.31: pyridoxamine—oxaloacetate transaminase EC 2.6.1.32: valine—3-methyl-2-oxovalerate transaminase EC 2.6.1.33: dTDP-4-amino-4,6-dideoxy-D-glucose transaminase EC 2.6.1.34: UDP-N-acetylbacillosamine transaminase EC 2.6.1.35: glycine—oxaloacetate transaminase EC 2.6.1.36: L-lysine 6-transaminase EC 2.6.1.37: (2-aminoethyl)phosphonate—pyruvate transaminase EC 2.6.1.38: histidine transaminase EC 2.6.1.39: 2-aminoadipate transaminase EC 2.6.1.40: (R)-3-amino-2-methylpropionate—pyruvate transaminase EC 2.6.1.41: D-methionine—pyruvate transaminase EC 2.6.1.42: branched-chain-amino-acid transaminase EC 2.6.1.43: aminolevulinate transaminase EC 2.6.1.44: alanine—glyoxylate transaminase EC 2.6.1.45: serine—glyoxylate transaminase EC 2.6.1.46: diaminobutyrate—pyruvate transaminase EC 2.6.1.47: alanine—oxomalonate transaminase EC 2.6.1.48: 5-aminovalerate transaminase EC 2.6.1.49: dihydroxyphenylalanine transaminase EC 2.6.1.50: glutamine—scyllo-inositol transaminase EC 2.6.1.51: serine—pyruvate transaminase EC 2.6.1.52: phosphoserine transaminase EC 2.6.1.53: Now EC 1.4.1.13, glutamate synthase (NADPH) EC 2.6.1.54: pyridoxamine-phosphate transaminase EC 2.6.1.55: taurine—2-oxoglutarate transaminase EC 2.6.1.56: 1D-1-guanidino-3-amino-1,3-dideoxy-scyllo-inositol transaminase EC 2.6.1.57: aromatic-amino-acid transaminase EC 2.6.1.58: phenylalanine(histidine) transaminase EC 2.6.1.59: dTDP-4-amino-4,6-dideoxygalactose transaminase EC 2.6.1.60: aromatic-amino-acid—glyoxylate transaminase EC 2.6.1.61: identical to EC 2.6.1.40, (R)-3-amino-2-methylpropionate—pyruvate transaminase EC 2.6.1.62: adenosylmethionine—8-amino-7-oxononanoate transaminase EC 2.6.1.63: kynurenine—glyoxylate transaminase EC 2.6.1.64: glutamine—phenylpyruvate transaminase EC 2.6.1.65: N6-acetyl-β-lysine transaminase EC 2.6.1.66: valine—pyruvate transaminase EC 2.6.1.67: 2-aminohexanoate transaminase EC 2.6.1.68: Now classified as EC 2.6.1.13, ornithine aminotransferase and EC 2.6.1.36, L-lysine 6-transaminase EC 2.6.1.69: identical to EC 2.6.1.11, ((acetylornithine transaminase))|identical to EC 2.6.1.11, acetylornithine transaminase EC 2.6.1.70: aspartate—phenylpyruvate transaminase EC 2.6.1.71: lysine—pyruvate 6-transaminase EC 2.6.1.72: D-4-hydroxyphenylglycine transaminase EC 2.6.1.73: methionine—glyoxylate transaminase EC 2.6.1.74: cephalosporin-C transaminase EC 2.6.1.75: cysteine-conjugate transaminase EC 2.6.1.76: diaminobutyrate—2-oxoglutarate transaminase EC 2.6.1.77: taurine—pyruvate aminotransferase EC 2.6.1.78: aspartate—prephenate aminotransferase EC 2.6.1.79: glutamate—prephenate aminotransferase EC 2.6.1.80: nicotianamine aminotransferase EC 2.6.1.81: succinylornithine transaminase EC 2.6.1.82: putrescine aminotransferase EC 2.6.1.83: LL-diaminopimelate aminotransferase EC 2.6.1.84: arginine—pyruvate transaminase EC 2.6.1.85: aminodeoxychorismate synthase EC 2.6.1.86: 2-amino-4-deoxychorismate synthase EC 2.6.1.87: UDP-4-amino-4-deoxy-L-arabinose aminotransferase EC 2.6.1.88: methionine transaminase EC 2.6.1.89: dTDP-3-amino-3,6-dideoxy-α-D-glucopyranose transaminase EC 2.6.1.90: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose transaminase EC 2.6.1.91: Identical to EC 2.6.1.34, UDP-N-acetylbacillosamine transaminase EC 2.6.1.92: UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine transaminase EC 2.6.1.93: neamine transaminase EC 2.6.1.94: 2′-deamino-2′-hydroxyneamine transaminase EC 2.6.1.95: neomycin C transaminase EC 2.6.1.96: 4-aminobutyrate—pyruvate transaminase EC 2.6.1.97: archaeosine synthase EC 2.6.1.98: UDP-2-acetamido-2-deoxy-ribo-hexuluronate aminotransferase EC 2.6.1.99: L-tryptophan—pyruvate aminotransferase EC 2.6.1.100: L-glutamine:2-deoxy-scyllo-inosose aminotransferase EC 2.6.1.101: L-glutamine:3-amino-2,3-dideoxy-scyllo-inosose aminotransferase EC 2.6.1.102: GDP-perosamine synthase EC 2.6.1.103: (S)-3,5-dihydroxyphenylglycine transaminase EC 2.6.1.104: 3-dehydro-glucose-6-phosphate—glutamate transaminase EC 2.6.1.105: lysine—8-amino-7-oxononanoate transaminase EC 2.6.1.106: dTDP-3-amino-3,4,6-trideoxy-α-D-glucose transaminase EC 2.6.1.107: β-methylphenylalanine transaminase EC 2.6.1.108: (5-formylfuran-3-yl)methyl phosphate transaminase EC 2.6.1.109: 8-amino-3,8-dideoxy-α-D-manno-octulosonate transaminase EC 2.6.1.110: dTDP-4-dehydro-2,3,6-trideoxy-D-glucose 4-aminotransferase EC 2.6.1.111: 3-aminobutanoyl-CoA transaminase EC 2.6.1.112: (S)-ureidoglycine—glyoxylate transaminase EC 2.6.1.113: putrescine—pyruvate transaminase EC 2.6.1.114: 8-demethyl-8-aminoriboflavin-5′-phosphate synthase EC 2.6.1.115: 5-hydroxydodecatetraenal 1-aminotransferase EC 2.6.1.116: 6-aminohexanoate aminotransferase EC 2.6.1.117: L-glutamine—4-(methylsulfanyl)-2-oxobutanoate aminotransferase EC 2.6.1.118: [amino-group carrier protein]-γ-(L-lysyl)-L-glutamate aminotransferase EC 2.6.1.119: vanillin aminotransferase
Sources: en.wikipedia.org
=== Teat flow rate === Teat characteristics can also have important implications for infant's sucking pattern and milk intake. Milk flow rate is defined as "the rate at which milk moves from the bottle nipple into the infant's mouth during bottle-feeding." Characteristics such as the shape of the nipple and the way it is perforated may impact flow rate and the coordination of sucking, swallowing and breathing during feeding. Unfortunately, categorization and labeling of teats to indicate flow rate is neither standardized nor consistent. There is significant variability between and within brands and models. In one study, nipples labeled "Slow" or "Newborn" (0–3 months) had flow rates ranging from 1.68 mL/min to 15.12 mL/min."The name assigned to the nipple type does not provide clear information to parents attempting to choose a nipple". This may be of extra concern in the case of fragile infants. Specialized teats are available for infants with cleft palate.
As seen in Figure 2, keto acid 1 was generated from the keto aldehyde that was converted to the silyl ether via asymmetric allylboration and silylation of the resulting alcohol. Ozonolysis of the silyl ether and Lindgren–Pinnick oxidation of the aldehyde afforded the keto acid. Ketone 2 was constructed via Enders alkylation starting from the hydrazone. Ozonolysis, the last step of the Enders alkylation, was followed by reduction of the aldehyde and silylation of the resulting alcohol. Hydrogenolysis of the benzyl ether gave the alcohol, which was oxidized under Swern condition and alkylated with the Grignard reagent to yield the secondary alcohol. Oxidation of this alcohol with the Ley–Griffith reagent gave the desired ketone. Thiazole 3 was synthesized from the ester, which was reduced with diisobutylaluminium hydride, and the aldehyde was reacted with the stabilized ylide in the Wittig reaction. Asymmetric allylboration of the α,β-unsaturated aldehyde and protection of the hydroxy group gave the silyl ether, whose terminal olefin was reacted with osmium tetroxide to a diol that was cleaved with lead tetraacetate to furnish the aldehyde. Reduction, iodination, and treatment with triphenylphosphine led to phosphonium salt.
The frequency of error during the DNA replication process of gametogenesis, especially amplified in the rapid production of sperm cells, can promote more opportunities for de novo mutations to replicate unregulated by DNA repair machinery. This claim combines the observed effects of increased probability for mutation in rapid spermatogenesis with short periods of time between cellular divisions that limit the efficiency of repair machinery. Rates of de novo mutations that affect an organism during its development can also increase with certain environmental factors. For example, certain intensities of exposure to radioactive elements can inflict damage to an organism's genome, heightening rates of mutation. In humans, the appearance of skin cancer during one's lifetime is induced by overexposure to UV radiation that causes mutations in the cellular and skin genome.
continuity (conservation of mass), conservation of linear momentum, conservation of angular momentum, conservation of energy. The study of fluids is fluid mechanics, which is subdivided into fluid dynamics and fluid statics depending on whether the fluid is in motion.
Pro-inflammatory myeloid cells along with production of the pro-inflammatory cytokines interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α) have been found to increase with age in rodents and humans. This is part of "inflammaging". Activation of these myeloid cells and consequent elevation in cytokine levels have been found to be suppressed by thymulin via inhibition of NF-κB signaling. Thymulin levels decrease with age.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.